In a separate blinded, randomised, multicentre trial for VRE infection at a variety of sites, intravenous low dose linezolid mg every 12 hours was compared to high dose therapy mg every 12 hours with optional conversion to oral administration.
Adverse effects of linezolid therapy have been predominantly gastrointestinal nausea, vomiting, diarrhoea , headache and taste alteration. This category includes daptomycin an acidic lipopeptide , oritavancin LY; a glycopeptide , and tigilcycline GAR; a novel analogue of minocycline.
Finally, strategies to suppress or eradicate the VRE intestinal reservoir have been reported for the combination of oral doxycyline plus bacitracin and oral ramoplanin a novel glycolipodepsipeptide. If successful, a likely application of such an approach is the reduction of VRE infection during high risk periods in high risk patient groups such as the post-chemotherapy neutropenic nadir or early post-solid abdominal organ transplantation.
Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website.
These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Necessary. Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website.
These cookies do not store any personal information. Non Necessary non-necessary. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. Uncategorized uncategorized. Accessed July 8, Murray BE. The life and times of the Enterococcus.
Clin Microbiol Rev. Evaluation of the treatment of vancomycin-resistant enterococcal urinary tract infections in a large academic medical center. Ann Pharmacother. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci.
Rubinstein E, Keynan Y. Vancomycin-resistant enterococci. Crit Care Clin. Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect Larchmt. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in U. Ann Intern Med.
Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist.
Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. Spacek LA. Diagnosis and Treatment of Infectious Diseases. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. Linden PK. Optimizing therapy for vancomycin-resistant enterococci VRE. Semin Respir Crit Care Med. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. Vancomycin-resistant enterococcal urinary tract infections.
Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis. Infect Control Hosp Epidemiol.
0コメント